ALNY Stock Overview
A biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Alnylam Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$272.05 |
52 Week High | US$274.93 |
52 Week Low | US$141.98 |
Beta | 0.37 |
11 Month Change | 8.37% |
3 Month Change | 79.90% |
1 Year Change | 46.59% |
33 Year Change | 39.35% |
5 Year Change | 236.78% |
Change since IPO | 4,426.62% |
Recent News & Updates
Recent updates
Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher
Aug 02RNAi: Winning In The Clinic, Now For The Market
Jun 25Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
Jun 03Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking
Mar 19Is Alnylam's HELIOS-B Delay A Red Flag?
Mar 10Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think
Feb 18Alnylam's Huge Opportunity
Jan 12Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues
Dec 18Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares
Jun 23Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?
Oct 25Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo
Oct 07Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market
Sep 26Alnylam RNAi therapy for rare protein disorder gets EU approval
Sep 20Alnylam to offer $900M convertible senior notes
Sep 12Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy
Aug 29Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity
Aug 18Shareholder Returns
ALNY | US Biotechs | US Market | |
---|---|---|---|
7D | 15.8% | -3.0% | -2.8% |
1Y | 46.6% | 15.5% | 16.6% |
Return vs Industry: ALNY exceeded the US Biotechs industry which returned 15.4% over the past year.
Return vs Market: ALNY exceeded the US Market which returned 16.6% over the past year.
Price Volatility
ALNY volatility | |
---|---|
ALNY Average Weekly Movement | 11.1% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 14.5% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALNY's share price has been volatile over the past 3 months.
Volatility Over Time: ALNY's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 2,100 | Yvonne Greenstreet | www.alnylam.com |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.
Alnylam Pharmaceuticals, Inc. Fundamentals Summary
ALNY fundamental statistics | |
---|---|
Market cap | US$34.93b |
Earnings (TTM) | -US$72.94m |
Revenue (TTM) | US$2.34b |
14.9x
P/S Ratio-478.8x
P/E RatioIs ALNY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALNY income statement (TTM) | |
---|---|
Revenue | US$2.34b |
Cost of Revenue | US$304.82m |
Gross Profit | US$2.04b |
Other Expenses | US$2.11b |
Earnings | -US$72.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.57 |
Gross Margin | 87.00% |
Net Profit Margin | -3.11% |
Debt/Equity Ratio | -79,140.2% |
How did ALNY perform over the long term?
See historical performance and comparison